Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
medical: Archive
Philips' (PHG) Reports Positive AI-Powered Cardiac Study Data
by Zacks Equity Research
Philips' (PHG) AI-powered cardiac monitoring solutions demonstrate significantly lower re-admissions and a higher rate of survival in the retrospective study evaluating it in stroke patients.
BSXPositive Net Change ECLPositive Net Change PHGNegative Net Change ALGNNegative Net Change
medical medical-devices
Masimo's (MASI) New Offering to Serve Personalized Audio Market
by Zacks Equity Research
Masimo's (MASI) new product offering is expected to enable it to expand its footprint in the personalized hearables market by offering personalized listening experiences.
ECLPositive Net Change DVAPositive Net Change MASIPositive Net Change VEEVNegative Net Change
medical medical-devices
Boston Scientific (BSX) Reaches 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Boston Scientific's (BSX) impressive market share gain in the MedSurg segment and continued geographical expansion.
BSXPositive Net Change ECLPositive Net Change DVAPositive Net Change VEEVNegative Net Change
medical medical-devices
BeiGene's (BGNE) Shares Surge 32% in a Month: Here's Why
by Zacks Equity Research
Beigene's (BGNE) shares surge 32% in a month due to the label expansion of one of its key oncology drugs, Tevimbra, to treat three NSCLC indications, including first- and second-line use, in the EU.
LGNDPositive Net Change ANIPPositive Net Change BGNEPositive Net Change ANVSPositive Net Change
biotechnology biotechs medical oncology-screening precious-metals
Top Stock Reports for UnitedHealth, Danaher & Abbott
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), Danaher Corporation (DHR) and Abbott Laboratories (ABT), as well as a micro-cap stock Ark Restaurants Corp. (ARKR).
ABTNegative Net Change CMENegative Net Change UNHNegative Net Change DHRPositive Net Change INTUPositive Net Change ARKRPositive Net Change MPCNegative Net Change
medical multi-sector-conglomerates
Here's Why You Should Retain UnitedHealth Group (UNH) Stock
by Zacks Equity Research
UnitedHealth Group (UNH) remains well-poised for growth on the back of a sound customer base, acquisitions and partnerships, the telehealth services suite, and growing cash reserves.
UNHNegative Net Change THCPositive Net Change ENSGNegative Net Change PNTGPositive Net Change
medical
IDEXX (IDXX) Witnesses Rising Expenses, Currency Issues
by Zacks Equity Research
IDEXX (IDXX) is being hurt by geopolitical instability, including the current war in Ukraine, which has affected supply chain operations globally.
IDXXNegative Net Change MEDPPositive Net Change HIMSPositive Net Change HITINegative Net Change
medical
Here's Why You Should Hold Surmodics (SRDX) Stock for Now
by Zacks Equity Research
Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.
DVAPositive Net Change ALGNNegative Net Change SRDXPositive Net Change MEDPPositive Net Change
medical medical-devices
Here's Why Investors Should Buy ResMed (RMD) Stock Now
by Zacks Equity Research
Investors are optimistic about ResMed's (RMD) potential in digital health and expansion in the international market.
RMDPositive Net Change MEDPPositive Net Change HIMSPositive Net Change HITINegative Net Change
medical medical-devices
AstraZeneca (AZN) to Build $1.5B Cancer Drug Plant in Singapore
by Zacks Equity Research
This new plant will be AstraZeneca's (AZN) first manufacturing facility for producing novel antibody drug conjugates from start to finish. It is scheduled to open in 2029.
AZNPositive Net Change PFENegative Net Change MRKPositive Net Change
biotechs medical pharmaceuticals
Boston Scientific (BSX) mCRM System Study Outcome Favorable
by Zacks Equity Research
Boston Scientific (BSX) mCRM System is designed to communicate wirelessly and coordinate painless intracardiac anti-tachycardia pacing (ATP) therapy.
BSXPositive Net Change RMDPositive Net Change MEDPPositive Net Change EHCPositive Net Change
medical medical-devices
Gilead (GILD) Announces Positive Interim Results on PBC Drug
by Zacks Equity Research
Gilead Sciences (GILD) experimental candidate, seladelpar, demonstrates significant improvements in liver disease progression and reduced itching in primary biliary cholangitis study.
GILDPositive Net Change LGNDPositive Net Change ANIPPositive Net Change
biotechnology biotechs medical pharmaceuticals
Implied Volatility Surging for Puma Biotechnology (PBYI) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Puma Biotechnology (PBYI) stock based on the movements in the options market lately.
PBYIPositive Net Change
biotechs medical
Medtronic (MDT) Reports Favorable SPHERE Per-AF Trial Outcome
by Zacks Equity Research
Medtronic's (MDT) Affera Mapping and Ablation System with Sphere-9 Catheter achieves endpoints for safety and efficacy for the treatment of AFib.
MDTNegative Net Change MEDPPositive Net Change HIMSPositive Net Change HITINegative Net Change
medical medical-devices
Company News for May 20, 2024
by Zacks Equity Research
Companies in The News Are: RBC,FLO,DOCS,GME
RBCPositive Net Change GMENegative Net Change FLOPositive Net Change DOCSPositive Net Change
consumer-staples industrial-products medical retail
The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen
by Zacks Equity Research
Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen are included in this Analyst Blog.
RHHBYNegative Net Change NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change ALTPositive Net Change VKTXPositive Net Change
medical
Veeva's (VEEV) Vault Basics to Boost Efficiency for Biotechs
by Zacks Equity Research
Veeva (VEEV) announces the availability of Vault Basics for biotechs, which aims to deliver complete and pre-validated solutions for expanding businesses.
BSXPositive Net Change ECLPositive Net Change ALGNNegative Net Change VEEVNegative Net Change
medical medical-devices
AxoGen (AXGN) Initiates BLA Submission for Avance Nerve Graft
by Zacks Equity Research
AxoGen (AXGN) starts the process of BLA submission to the FDA for the approval of its Avance Nerve Graft.
BSXPositive Net Change ECLPositive Net Change ALGNNegative Net Change AXGNPositive Net Change
medical medical-devices
BD's (BDX) FDA-Approved Test to Offer Wider Testing Access
by Zacks Equity Research
BD's (BDX) receipt of the FDA's clearance for the use of self-collected vaginal specimens for HPV testing is likely to improve screening access to a wider female population.
ECLPositive Net Change BDXPositive Net Change DVAPositive Net Change VEEVNegative Net Change
medical medical-devices
Here's Why Incyte (INCY) Stock is Up More Than 7% in a Week
by Zacks Equity Research
Incyte (INCY) rises 7% in a week as investors appreciated the company's buyback plan to boost returns.
INCYPositive Net Change LGNDPositive Net Change ANIPPositive Net Change
biotechnology biotechs medical pharmaceuticals
Haemonetics' (HAE) Hospital & Plasma Segments, Innovation Aid
by Zacks Equity Research
Haemonetics' (HAE) hospital portfolio is evolving and helping to create new opportunities for growth and diversification.
RMDPositive Net Change HAENegative Net Change MEDPPositive Net Change EHCPositive Net Change
medical
Eli Lilly's (LLY) Efsitora Matches Daily Insulins in A1C Control
by Zacks Equity Research
Eli Lilly's (LLY) two phase III studies on its once-weekly insulin, efsitora alfa, meet their primary endpoint of non-inferior reduction in blood sugar levels compared with daily basal insulins.
LLYPositive Net Change LGNDPositive Net Change ANIPPositive Net Change ANVSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Maravai (MRVI) Advances in RNA Research With New Collaboration
by Zacks Equity Research
Per Maravai LifeSciences (MRVI) management, this development by TriLink is set to advance nucleic acid-based therapies.
RMDPositive Net Change MEDPPositive Net Change EHCPositive Net Change MRVINegative Net Change
medical
Haemonetics (HAE) Stock Up 10.9% YTD: Will the Rally Continue?
by Zacks Equity Research
Investors are optimistic about Haemonetics (HAE) led by its strategic focus on establishing leading positions in high-growth markets to generate solid financial returns.
RMDPositive Net Change HAENegative Net Change MEDPPositive Net Change EHCPositive Net Change
medical medical-devices
Ionis (IONS), Biogen Down on Ending Development of ALS Drug
by Zacks Equity Research
Ionis (IONS) and Biogen (BIIB) stop developing their experimental ALS drug after a phase I/II study failed to show improvement in patients.
BIIBPositive Net Change LGNDPositive Net Change HRTXPositive Net Change IONSPositive Net Change
biotechs medical pharmaceuticals